Core Insights - The company reported a revenue of RMB 286.04 billion for the first half of 2025, a decrease of 2.95% compared to the same period last year [1] - Net profit and attributable net profit were RMB 5.34 billion and RMB 3.47 billion, reflecting year-on-year declines of 9.53% and 6.43% respectively [1] Revenue Breakdown - The pharmaceutical distribution segment maintained stable development, with its revenue share decreasing by 0.48 percentage points to 73.62% [1] - The medical device distribution revenue saw a slight decline, with its revenue share increasing by 0.08 percentage points to 19.22% [1] - The pharmaceutical retail segment experienced growth, with its revenue share increasing by 0.36 percentage points to 5.78% [1] Cost Management - The company demonstrated effective cost control, benefiting from reduced financing costs, integrated management measures, and lower business costs [1] - The sales expense ratio, management expense ratio, and financial expense ratio decreased to 2.74%, 1.28%, and 0.35% respectively, with a total optimization of 0.2 percentage points [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 SINOPHARM GROUP CO. LTD. * （於中華人民共和國註冊成立之股份有限公司， 在香港以國控股份有限公司之名稱經營業務） （股份代號：01099） 二零二五年中期業績公告 國藥控股股份有限公司（「本公司」、「公司」或「國藥控股」）董事會（「董事會」）欣然宣佈本 公司及其附屬公司（「本集團」）截至二零二五年六月三十日止六個月期間（「報告期間」或 「報告期」）之未經審核中期業績，連同去年同期的比較資料如下： * 本公司以其中文名稱及英文名稱「Sinopharm Group Co. Ltd.」根據香港公司條例註冊為非香 港公司。 - 1 - 中期簡明綜合損益表 截至二零二五年六月三十日止六個月 | | | 截至六月三十日止六個月 | | | --- | --- | --- | --- | | | 附註 | 二零二五年 | 二零二四年 | | | | 人民幣千元 | 人民幣千元 | | | | ...

Core Insights - The Invesco Great Wall State-Owned Enterprise Value Mixed A Fund (018294) has a latest net value of 1.3787 yuan, with a weekly return of -0.04%, a three-month return of 11.07%, and a year-to-date return of 14.41% [1] - The fund was established on May 30, 2023, and managed by Zou Lihua, with a total scale of 295 million yuan as of June 30, 2025 [1] - The top ten stock holdings of the fund include Zijin Mining, China Mobile, Shenhuo Co., Tencent Holdings, China National Offshore Oil, Chuan Yi Co., Sinopharm Holdings, Zhuhai Mining, Yun Aluminum, and CRRC Corporation, accounting for a total of 52.32% of the portfolio [1]

Performance Summary - China Petroleum & Chemical Corporation (00386.HK) reported a revenue of 1,409.05 billion yuan, a decrease of 10.6% year-on-year, and a net profit of 21.483 billion yuan, down 39.8% year-on-year [2] - Kuaishou Technology (01024.HK) achieved a revenue of 67.654 billion yuan, an increase of 12.04% year-on-year, with a net profit of 8.9 billion yuan, up 9.9% year-on-year [2] - China National Pharmaceutical Group (01099.HK) recorded a revenue of 36.363 billion yuan, a decrease of 1.48% year-on-year, and a net profit of 295 million yuan, an increase of 1.02% year-on-year [2] - Miniso Group (09896.HK) reported a revenue of 9.393 billion yuan, a growth of 21.1% year-on-year, but a net profit of 906 million yuan, down 22.6% year-on-year [2] - Tuhu (09690.HK) had a revenue of 7.9 billion yuan, an increase of 10.5% year-on-year, with an adjusted net profit of 410 million yuan, up 14.6% year-on-year, and the number of stores increased to 7,205 [2] - Bilibili Inc. (09626.HK) reported a second-quarter revenue of 7.338 billion yuan, an increase of 19.76% year-on-year, and a net profit of 219 million yuan, turning from a loss of 609 million yuan in the same period last year [2] - Zaitong (00062.HK) achieved a revenue of 4.226 billion HKD, an increase of 3.98% year-on-year, and a net profit of 190 million HKD, up 57.94% year-on-year [2] - Xincheng Power (01148.HK) reported a revenue of 2.804 billion yuan, an increase of 7.06% year-on-year, but a net profit of 16.49 million yuan, down 25.49% year-on-year [2] - Fourth Paradigm (06682.HK) achieved a revenue of 2.626 billion yuan, an increase of 40.71% year-on-year, with an adjusted net loss of 44 million yuan, narrowing by approximately 71.2% from a loss of 152 million yuan in the same period last year [2] - Meilian Group (01200.HK) reported a revenue of 2.518 billion HKD, a decrease of 24.1% year-on-year, and a net profit of 151 million HKD, down 13% year-on-year [2] - Baisheng Group (03368.HK) achieved a revenue of 1.963 billion yuan, an increase of 0.93% year-on-year, and a net profit of 22.468 million yuan, turning from a loss of 18.641 million yuan in the same period last year [2] - Yuexiu Services (06626.HK) reported a revenue of approximately 1.962 billion yuan, a slight increase of 0.09% year-on-year, with a net profit of approximately 240 million yuan [2] - Yika (09923.HK) achieved a revenue of 1.64 billion yuan, an increase of 4% year-on-year, and a net profit of 43.075 million yuan, up 36.2% year-on-year [2] - Gaoweidianzi (01415.HK) reported a revenue of 1.36 billion USD, an increase of 132.2% year-on-year, with a net profit of 67.398 million USD, up approximately 320% year-on-year [2] - BOC Aviation (02588.HK) achieved a revenue of 1.242 billion USD, an increase of 6% year-on-year, but a net profit of 342 million USD, down 26% year-on-year [2] - Jiuxing Holdings (01836.HK) reported a revenue of 775 million USD, an increase of 0.7% year-on-year, but a net profit of 78.633 million USD, down 14.5% year-on-year [2] - Sinopec Kantons Holdings (00934.HK) reported a revenue of approximately 307 million HKD, a decrease of 7.2% year-on-year, and a net profit of approximately 563 million HKD, down 17.8% year-on-year [2] - Great Wall Holdings (00583.HK) issued a profit warning, expecting a mid-term net loss of 266 million to 294 million HKD, a significant shift from profit to loss [2] Company News - Shengye (06069.HK) has initiated a global strategic layout to build an AI + international supply chain technology platform [2] - Yuan Zheng Technology (02488.HK) plans to develop a strategic layout for equipment assetization and related RWA applications [2] - Oconview Biosciences (01477.HK) announced that the second Phase III clinical trial of OT-301 has reached its primary endpoint [2] Buyback Activities - Tencent Holdings (00700.HK) repurchased 928,000 shares at a cost of 551 million HKD, with a buyback price ranging from 590 to 597 HKD [2] - HSBC Holdings (00005.HK) repurchased approximately 1.33 million shares at a cost of about 132 million HKD, with a buyback price ranging from 98.6 to 99.55 HKD [2] - Techtronic Industries (00669.HK) repurchased approximately 25,000 shares at a cost of about 25.085 million HKD, with a buyback price ranging from 99.5 to 101.6 HKD [2] - Hang Seng Bank (00011.HK) repurchased 200,000 shares at a cost of 22.4935 million HKD, with a buyback price ranging from 111.8 to 112.8 HKD [2]

Group 1 - The core viewpoint of the article highlights the financial performance of China National Pharmaceutical Group Corporation (国药控股) for the six months ending June 30, 2025, indicating a slight decline in revenue and operating profit, while showing a modest increase in comprehensive income attributable to the parent company [1] Group 2 - The company reported operating revenue of 36.363 billion RMB, representing a year-on-year decrease of 1.48% [1] - Operating profit was recorded at 684 million RMB, reflecting a year-on-year decline of 8.28% [1] - Comprehensive income attributable to the parent company was 295 million RMB, which is a year-on-year increase of 1.02% [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚賴該 等內容而引致之任何損失承擔任何責任。 * 本公司以其中文名稱及英文名稱「 Sinopharm Group Co. Ltd. 」根據香港公司條例註冊為非香港公司。 1 國藥器械之合併財務報表之主要未經審核財務數據 單位：元 幣種：人民幣 | | | | 本報告期 | | --- | --- | --- | --- | | | 本報告期 | 上年同期 | 比上年同期增減 | | 營業收入 | 36,362,746,042.44 | 36,908,522,536.26 | -1.48% | | 營業利潤 | 684,176,599.68 | 745,979,066.39 | -8.28% | | 歸屬於母公司所有者的 綜合收益總額 | 294,606,310.11 | 291,632,700.32 | 1.02% | | 經營活動產生的現金流 | -2,481,582,321.54 | -7,726,076,201.83 | -67.88% | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完整性 亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致 之任何損失承擔任何責任。 海外監管公告 中國醫療器械有限公司 2025 年半年度報告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條作出。 茲載列國藥控股股份有限公司旗下一間附屬公司，中國醫療器械有限公司於 2025 年 8 月 21 日 於中國貨幣網及上海清算所網站刊發的《中國醫療器械有限公司 2025 年半年度報告》，僅供參 閱。 承董事會命 國藥控股股份有限公司 董事長 趙炳祥 中國，上海 2025 年 8 月 21 日 於本公告日期，執行董事為連萬勇先生及孫京林先生；非執行董事為趙炳祥先生、陳啟宇先生、 祖敬 先生、邢永剛先生、陳玉卿先生、文德鏞先生及馮蓉麗女士；獨立非執行董事為李培育先生、 吳德龍 先生、俞衛鋒先生、石晟昊先生及陳威如先生。 * 本公司以其中文名稱及英文名稱「 Sinopharm Group Co. Ltd. 」根據香港公司條例註冊為非香港公司。 中国医疗器械有限公司 - 3 - 1 ...

Group 1 - The core viewpoint of the article is that China National Pharmaceutical Group (国药控股) reported its subsidiary China National Pharmaceutical Co., Ltd. (国药股份) financial performance for the first half of 2025, showing a slight increase in revenue but a decline in net profit [1] - The operating revenue for the first half of 2025 was approximately 25.634 billion yuan, representing a year-on-year growth of 3.54% [1] - The net profit attributable to shareholders of the listed company was approximately 949 million yuan, reflecting a year-on-year decrease of 5.19% [1] - The basic earnings per share were reported at 1.2572 yuan [1]

公告 國藥股份截至 2025 年 6 月 30 日止六個月之 主要未經審核會計數據和財務指標 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.09 條及證券及期貨條例（香港法例第 571 章）第 XIVA 部刊發。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚賴該 等內容而引致之任何損失承擔任何責任。 茲提述國藥控股股份有限公司（「本公司」）於 2025 年 8 月 20 日刊發之海外監管公告（「該公 告」），内容有關本公司附屬公司國藥集團藥業股份有限公司（「國藥股份」，其 A 股於上海證 券交易所上市（股票代碼：600511））之 2025 年半年度報告。 本公司董事會謹此提醒股東及公眾投資者注意以下於該公告內載列之國藥股份截至 2025 年 6 月 30 日止六個月（「報告期」）之主要未經審核會計數據和財務指標。 單位：元 幣種：人民幣 本报告期末比 | | 本報告期末 | 上年度末 | 上年度末增减 | (%) | | --- | --- | --- | --- | --- ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完整性 亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致 之任何損失承擔任何責任。 海外監管公告 國藥集團藥業股份有限公司 2025 年半年度報告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條作出。 茲載列國藥控股股份有限公司旗下一間 A 股於上海證券交易所上市的附屬公司，國藥集團藥業 股份有限公司，於 2025 年 8 月 20 日於上海證券交易所網站刊發的《國藥集團藥業股份有限公 司 2025 年半年度報告》，僅供參閱。 承董事會命 國藥控股股份有限公司 董事長 趙炳祥 中國，上海 2025 年 8 月 20 日 於本公告日期，執行董事為連萬勇先生及孫京林先生；非執行董事為趙炳祥先生、陳啟宇先生、祖敬先 生、邢永剛先生、陳玉卿先生、文德鏞先生及馮蓉麗女士；獨立非執行董事為李培育先生、吳德龍先生、 俞衛鋒先生、石晟昊先生及陳威如先生。 * 本公司以其中文名稱及英文名稱「 Sinopharm Group Co. Ltd. 」根據香港公司條例註冊為非香港公司。 国药 ...